Skip to main content

Lyrics I admire

Michael Bolton

Michael Bolton's big hit "How am I Supposed to Live without You" begins thus:

"I could hardly believe it/When I heard the news today/I had to come and get it straight from you/They said you were leavin'/Someone swept your heart away/From the look upon your face I see it's true."

That  strikes me as a marvelous bit of story telling. The rest of the song, unfortunately, soon slips into standard-issue '80s ballad.

But what exactly do I like about the above?

The first line sets up the rest, pressing the listener to ask what was so unbelievable.

We might guess that a romantic disappointment was the hardly-believed thing, but we are steered subtly in another direction by "when I heard the news today." That's very different from, say, "when the gossip reached my ears" or "when someone told me so." We've come to regard the news as something authoritative and public in nature. The Beatles played on this same expectation in "A Day in the Life," which has "I read the news today" in the first line.

So Bolton starts with "I could hardly believe it," then mentions hearing "news." Our expectations are sifting again in the line that follows that. "I had to come and get it straight from you."

"You" it seems clear, isn't you, the listener within earshot of a radio. The "you" is a person at the center of the "news" in question. Yet it is the fourth line that tells us our original likely-expectation was right after all. The "news" is of a breaking-up sort.

The fifth line indicates that the narrator heard this "news" from more than one source while remaining incredulous. "They" said. Not just one mutual acquaintance. This makes the initial incredulity a more solid fact.

I could go on, but I won't. This was good writing. That's the only point.

Comments

Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.



We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

Hume's Cutlery

David Hume is renowned for two pieces of cutlery, the guillotine and the fork.

Hume's guillotine is the sharp cut he makes between "is" statements and "ought" statements, to make the point that the former never ground the latter.

His "fork" is the division between what later came to be called "analytic" and "synthetic" statements, with the ominous observation that any books containing statements that cannot be assigned to one or the other prong should be burnt.

Actually, I should acknowledge that there is some dispute as to how well or poorly the dichotomy Hume outlines really maps onto the analytic/synthetic dichotomy. Some writers maintain that Hume meant something quite different and has been hijacked. Personally, I've never seen the alleged difference however hard they've worked to point it out to me.

The guillotine makes for a more dramatic graphic than a mere fork, hence the bit of clip art above.

I'm curious whe…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…